Abstract

RECENT TRENDS IN DENGUE VACCINE DEVELOPMENT

Vanita Baliram Jadhav*, Prof. Shahebaz Deshmukh and Prof. L. D. Hingane

ABSTRACT

Dengue is a mosquito-borne disease it is currently expanding by global health problem. This disease is caused by 4 closed related viruses, of dengue virus. There are no specific dengue therapeutics and prevention is currently limited to vector control measures. Development of an effective tetravalent dengue vaccine would therefore represent a major advance in the control of the disease and is considered a high public health priority. A licensed dengue vaccine is not available, the scope and intensity of dengue vaccine development has increased dramatically in the last decade. The uniqueness of the dengue viruses and the spectrum of disease resulting from infection have made dengue vaccine development difficult. Several vaccine candidates are currently being evaluated in clinical studies. The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on chimeric yellow fever dengue virus, has progressed to phase 3 efficacy, studies. Several other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccines candidates, are at earlier stages of clinical development. Additional technological approaches, such as virus-vectored and virus-like particle-based vaccines, are under evaluation in preclinical studies.

Keywords: Dengue infection, dengue fever, dengue vaccines, Flavivirus, live-attenuated tetravalent vaccine, development.